Search
Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15682ApprovedInvestigationalCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideInterferon gamma-1b
go.drugbank.com/drugs/DB00033ApprovedInvestigationalThe sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. … Purification of the product is achieved by conventional column chromatography.
Framycetin
go.drugbank.com/drugs/DB00452ApprovedInvestigationalA component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
International brands: Leukase NBeclamide
go.drugbank.com/drugs/DB09011ExperimentalIt was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures. … Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.
Tilbroquinol
go.drugbank.com/drugs/DB13222ApprovedTilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467]. … In Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis.
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized … [A232613,A232573] Pimavanserin is marketed under the trade name NUPLAZID and developed by Acadia Pharmaceuticals.
Velpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune
Darunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigational[L9227] As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. … [L9227] Darunavir is being studied as a possible treatment for SARS-CoV-2, the coronavirus responsible for COVID-19, due to in vitro evidence supporting its ability to combat this infection.
Mixtures: VIRONTAR N COMPRIMIDOS RECUBIERTOS, VIRONTAR N COMPRIMIDOS RECUBIERTOSSynonyms: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate, (3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamateOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigationalOrforglipron is a first-in-class oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. … [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.